Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis

Perera, Marlon; Papa, Nathan; Christidis, Daniel; Wetherell, David; Hofman, Michael S; Murphy, Declan; Bolton, Damien; Lawrentschuk, Nathan

doi:10.1016/j.eururo.2016.06.021

Cited by 841 publications

(624 citation statements)

References 57 publications

Supporting

Mentioning

570

Contrasting

Unclassified

Order By: Relevance

“…A first metaregression analysis in a systematic review including 10 studies was recently published. It resulted in a predicted PSMA ligand PET/CT positivity rate of 42%, 58%, 76%, and 95% for PSA values of 0-0.2, 0.2-1, 1-2, and more than 2 ng/mL, respectively (42). However, the results of this analysis need to be interpreted with caution as different 68 Ga-PSMA-based PET tracers were pooled and no systematic histologic verification was available.…”

Section: Main Clinical Indications Of Psma Ligand Pet/ct and Current mentioning

confidence: 82%

PSMA Ligands for PET Imaging of Prostate Cancer

et al. 2017

View full text Add to dashboard Cite

Section: Main Clinical Indications Of Psma Ligand Pet/ct and Current mentioning

confidence: 82%

PSMA Ligands for PET Imaging of Prostate Cancer

et al. 2017

View full text Add to dashboard Cite

“…In a recent study, Minamimoto et al (30) compared PSMA and GRPR-targeted imaging in prostate cancer and found no significant differences. Furthermore, Perera et al (31) reported on a relatively low sensitivity of PSMA-targeted imaging in patients with low prostate-specific antigen levels and patients with primary disease (40% and 50%, respectively). Especially in these patient groups, the application of GRPR radioligands may be of benefit.…”

Section: Discussionmentioning

confidence: 99%

⁶⁸Ga/¹⁷⁷Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology

et al. 2016

View full text Add to dashboard Cite

Because overexpression of the gastrin-releasing peptide receptor (GRPR) has been reported on various cancer types, for example, prostate cancer and breast cancer, targeting this receptor with radioligands might have a significant impact on staging and treatment of GRPR-expressing tumors. NeoBOMB1 is a novel DOTAcoupled GRPR antagonist with high affinity for GRPR and excellent in vivo stability. The purpose of this preclinical study was to further explore the use of NeoBOMB1 for theranostic application by determining the biodistribution of 68 Ga-NeoBOMB1 and 177 LuNeoBOMB1. Methods: PC-3 tumor-xenografted BALB/c nu/nu mice were injected with either approximately 13 MBq/250 pmol 68 GaNeoBOMB1 or a low (;1 MBq/200 pmol) versus high (;1 MBq/10 pmol) peptide amount of 177 Lu-NeoBOMB1, after which biodistribution and imaging studies were performed. At 6 time points (15,30, 60, 120, 240, and 360 min for 68 4,24, 48, 96, and 168 h for 177 Lu-NeoBOMB1) postinjection tumor and organ uptake was determined. To assess receptor specificity, additional groups of animals were coinjected with an excess of unlabeled NeoBOMB1. Results of the biodistribution studies were used to determine pharmacokinetics and dosimetry. Furthermore, PET/CT and SPECT/MRI were performed. Results: Injection of approximately 250 pmol 68 Ga-NeoBOMB1 resulted in a tumor and pancreas uptake of 12.4 6 2.3 and 22.7 6 3.3 percentage injected dose per gram (%ID/g) of tissue, respectively, at 120 min after injection. 177 Lu-NeoBOMB1 biodistribution studies revealed a higher tumor uptake (17.9 6 3.3 vs. 11.6 6 1.3 %ID/g of tissue at 240 min after injection) and a lower pancreatic uptake (19.8 6 6.9 vs. 105 6 13 %ID/g of tissue at 240 min after injection) with the higher peptide amount injected, leading to a significant increase in the absorbed dose to the tumor versus the pancreas (200 pmol, 570 vs. 265 mGy/ MBq; 10 pmol, 435 vs. 1393 mGy/MBq). Using these data to predict patient dosimetry, we found a kidney, pancreas, and liver exposure of 0.10, 0.65, and 0.06 mGy/MBq, respectively. Imaging studies resulted in good visualization of the tumor with both 68 Ga-NeoBOMB1 and 177 Lu-NeoBOMB1. Conclusion: Our findings indicate that 68 Ga-or 177 Lu-labeled NeoBOMB1 is a promising radiotracer with excellent tumor uptake and favorable pharmacokinetics for imaging and therapy of GRPR-expressing tumors.

show abstract

“…It has also incorporated the development of, and is freely available to, medical students. Providing an avenue for ease of access to contributions in current projects, in addition to a communication nexus where questions are answered and advice is given by senior researchers who have experience within the field of Urology research.Despite its infancy, early successes can be seen in YURO's involvement in several publications [3][4][5]. In addition to regular education sessions with medical students and perhaps most importantly, an ongoing dialogue between junior members interested in improving their research methods and experienced members interested in sharing their wisdom.…”

mentioning

confidence: 99%

“…Despite its infancy, early successes can be seen in YURO's involvement in several publications [3][4][5]. In addition to regular education sessions with medical students and perhaps most importantly, an ongoing dialogue between junior members interested in improving their research methods and experienced members interested in sharing their wisdom.…”

mentioning

confidence: 99%

“Collaboration Through Communication”: The Young Urology Researchers Organisation (YURO)

et al. 2016

Self Cite

View full text Add to dashboard Cite

In an ideal world, research to investigate the effects of a phenomenon would be measured on a population scale. The benefits of open access and lateral sharing of resources, data and staff across clinical centres are extensive. Unfortunately, logistics often limit study sample sizes to single centre cohorts whose findings may be influenced by confounding factors and are not translatable to the wider community. To combat this, multi-centre trials have been endorsed to upscale the statistical power and significance of scientific research findings to benefit patients and clinicians alike. Large-scale multicentre trials such as STAMPEDE [1] are clear examples of how findings of relationships of causality are strengthened through larger sample sizes. Such studies are often birthed through significant financial support and networks that senior clinicians built through years of practice, or by large well funded trials groups such as the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group.Certainly, younger and more inexperienced researchers seldom get the chance to contribute to the existing large-scale collaboration projects and few structured avenues are available to advise and support those who are new to healthcare research. Juniors and trainees have found it difficult to acquire the requisite skills to produce high quality work and it is often presumed sometimes incorrectly, that with time and career development, these skills will be cultivated without the aid of a formal body to do so.With the recent advent of social media and communication technologies, the ability of professionals to network and communicate has never been greater. Further to this, involvement of senior clinicians in these forums and online dialogue allows for teaching and review of junior researchers and trainees. It is this innovative style of interaction and cooperation that has led to the formation of several groups driven by young researchers, guided by senior clinicians, that have the aim of producing high-quality research through collaborative efforts.The Young Urology Researchers Organisation (YURO) is one such organization, formed by a select few likeminded people, with the intention of contributing to the wider academic community of Australian urological research. The group was legitimized in 2016 with its first annual assembly at the Urological Society of Australia and New Zealand's annual scientific meeting. Run exclusively by its members, the organization aims to increase the validity of its research efforts by combining data and findings across multiple institutions. Currently, representatives from over 9 clinical sites including rural Victoria and New Zealand are involved, with plans to expand into other states. Members communicate via several avenues including formal committee meetings, a website [2] an online project log available to all members and a centralized email account. This open online forum affords members the ability to bounce project ideas off one another, review fellow colleague's work and...

show abstract

Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis

Cited by 841 publications

References 57 publications

PSMA Ligands for PET Imaging of Prostate Cancer

PSMA Ligands for PET Imaging of Prostate Cancer

⁶⁸Ga/¹⁷⁷Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology

“Collaboration Through Communication”: The Young Urology Researchers Organisation (YURO)

Contact Info

Product

Resources

About

Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis

Cited by 841 publications

References 57 publications

PSMA Ligands for PET Imaging of Prostate Cancer

PSMA Ligands for PET Imaging of Prostate Cancer

68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology

“Collaboration Through Communication”: The Young Urology Researchers Organisation (YURO)

Contact Info

Product

Resources

About

⁶⁸Ga/¹⁷⁷Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology